CoChat
Sign Up
Cited by 43Schizophrenia research and treatmentTreatment of Major DepressionNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid

Calabrese, F., Luoni, A., Guidotti, G., Racagni, G., Fumagalli, F., Riva, M. A.·2013·Psychopharmacology
DOI 10.1007/s00213-012-2900-0
Open this paper in CoChat — free account

Abstract

Rationale Combinatory therapy is widely used in psychiatry owing to the possibility that drugs with different mechanisms of action may synergize to improve functions deteriorated in schizophrenia, bipolar disorders, and major depression. While combinatory strategies rely on receptor and synaptic mechanisms, it should also be considered that two drugs may also "interact" on the long-term to determine more robust changes in neuronal plasticity, which represents a downstream target important for functional recovery. Objective The aim of the study is to investigate neuroadaptive changes set in motion by chronic concomitant administration of the novel antipsychotic lurasidone and the mood stabilizer valproate. Methods Animals were chronically treated with lurasidone, valproate, or the combination of the two drugs and killed 24 h after the last injection to evaluate alterations of different measures of neuronal plasticity such as the neurotrophin brain-derived neurotrophic factor (BDNF), the immediate early gene Activity-regulated cytoskeletal associated protein, and the epigenetic regulators HDAC 1, 2, and 5 in dorsal and ventral hippocampus. Results The results suggest that coadministration of lurasidone and valproate produces, when compared to the single drugs, a larger increase in the expression of BDNF in the ventral hippocampus, through the regulation of specific neurotrophin transcripts. We also found that the histone deacetylases were regulated by the drug combination, suggesting that some of the transcriptional changes may be sustained by epigenetic mechanisms. Conclusions Our results suggest that the beneficial effects associated with combinatory treatment between a second-generation antipsychotic and a mood stabilizer could result from the ability to modulate neuroplastic molecules, whose expression and function is deteriorated in different psychiatric conditions.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00213-012-2900-0

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 48

  1. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T (2007) Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 85:525–535 · DOI · Paper page
  2. An JJ, Gharami K, Liao GY, Woo NH, Lau AG, Vanevski F, Torre ER, Jones KR, Feng Y, Lu B, Xu B (2008) Distinct role of long 3′ UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 134:175–187 · DOI
  3. Baj G, Leone E, Chao MV, Tongiorgi E (2011) Spatial segregation of BDNF transcripts enables BDNF to differentially shape distinct dendritic compartments. Proc Natl Acad Sci U S A 108:16813–16818 · DOI
  4. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG et al (1994) Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Jama 271:918–924 · DOI · Paper page
  5. Bowden CL, Myers JE, Grossman F, Xie Y (2004) Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry 65:707–714 · DOI
  6. Bramham CR, Messaoudi E (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76:99–125 · DOI · Paper page
  7. Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, Pai B, Panja D, Schubert M, Soule J, Tiron A, Wibrand K (2010) The Arc of synaptic memory. Exp Brain Res 200:125–140 · DOI · Paper page
  8. Calabrese F, Molteni R, Maj PF, Cattaneo A, Gennarelli M, Racagni G, Riva MA (2007) Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 32:2351–2359 · DOI
  9. Calabrese F, Molteni R, Racagni G, Riva MA (2009) Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 34(Suppl 1):S208–S216 · DOI
  10. Calabrese F, Molteni R, Cattaneo A, Macchi F, Racagni G, Gennarelli M, Ellenbroek BA, Riva MA (2010) Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Mol Pharmacol 77:846–853 · DOI
  11. Calabrese F, Molteni R, Gabriel C, Mocaer E, Racagni G, Riva MA (2011) Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl) 215:267–275 · DOI
  12. Chen G, Henter ID, Manji HK (2010) Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 15:883–895 · DOI · Paper page
  13. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM (2002) A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41:1216–1223 · DOI
  14. Dynes JL, Steward O (2007) Dynamics of bidirectional transport of Arc mRNA in neuronal dendrites. J Comp Neurol 500:433–447 · DOI
  15. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23:7311–7316 · DOI
  16. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A (2008) Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 186:197–207 · DOI
  17. Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A, Severus E, Versiani M, Tandon R, Moller HJ, Vieta E (2012) Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 262(Suppl 1):1–48 · DOI
  18. Fumagalli F, Frasca A, Racagni G, Riva MA (2008) Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol 73:1484–1490 · DOI
  19. Fumagalli F, Frasca A, Racagni G, Riva MA (2009) Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms. CNS Drugs 23:603–614 · DOI
  20. Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA (2012) Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 15:235–246 · DOI
  21. Grayson DR, Chen Y, Dong E, Kundakovic M, Guidotti A (2009) From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia. Epigenetics 4:144–149 · DOI
  22. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS (2011) Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 127:188–194 · DOI
  23. Huang M, Horiguchi M, Felix AR, Meltzer HY (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23:436–440 · DOI
  24. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171–181 · DOI
  25. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (2007) Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160–170 · DOI
  26. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167:1305–1320 · DOI
  27. Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G, Xia M, Fritsch B, Zheng JQ, Dingledine R, Xu B, Lu B, Feng Y (2010) Distinct 3′UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF). Proc Natl Acad Sci U S A 107:15945–15950 · DOI
  28. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG (2008) Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60:358–403 · DOI
  29. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, Gilbert DJ, Jenkins NA, Lanahan AA, Worley PF (1995) Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 14:433–445 · DOI
  30. Maragnoli ME, Fumagalli F, Gennarelli M, Racagni G, Riva MA (2004) Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 55:1095–1102 · DOI
  31. Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R (2011) Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 13:133–144 · DOI
  32. Meyer JM, Loebel AD, Schweizer E (2009) Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18:1715–1726 · DOI
  33. Molteni R, Calabrese F, Racagni G, Fumagalli F, Riva MA (2009) Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 124:74–85 · DOI
  34. Molteni R, Calabrese F, Pisoni S, Gabriel C, Mocaer E, Racagni G, Riva MA (2010) Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 11:148–153 · DOI
  35. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70:829–836 · DOI
  36. Nivoli AM, Murru A, Goikolea JM, Crespo JM, Montes JM, Gonzalez-Pinto A, Garcia-Portilla P, Bobes J, Saiz-Ruiz J, Vieta E (2012) New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord 140:125–141 · DOI
  37. Park SW, Phuong VT, Lee CH, Lee JG, Seo MK, Cho HY, Fang ZH, Lee BJ, Kim YH (2011) Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci Res 71:335–340 · DOI
  38. Paxinos G, Watson C (1996) The rat brain in stereotaxis coordinates. Academic, New York
  39. Pruunsild P, Sepp M, Orav E, Koppel I, Timmusk T (2011) Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J Neurosci 31:3295–3308 · DOI
  40. Riva MA, Molteni R, Tascedda F, Massironi A, Racagni G (1999) Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology 38:1075–1082 · DOI
  41. Roth TL, Lubin FD, Sodhi M, Kleinman JE (2009b) Epigenetic mechanisms in schizophrenia. Biochim Biophys Acta 1790:869–877, Epub 2009 Jun 25 · DOI
  42. Schloesser RJ, Martinowich K, Manji HK (2012) Mood-stabilizing drugs: mechanisms of action. Trends Neurosci 35:36–46 · DOI
  43. Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, Riva MA (2001) Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50:117–122 · DOI
  44. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A (2002) Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59:62–69 · DOI
  45. Tomasetti C, Dell'Aversano C, Iasevoli F, Marmo F, de Bartolomeis A (2011) The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiat 35:184–197 · DOI
  46. Vieta E, Gunther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Astrom M, Paulsson B (2011) Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 14:1029–1049 · DOI
  47. Wong EH, Tarazi FI, Shahid M (2010) The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol Ther 126:173–185 · DOI
  48. Xu H, Qing H, Lu W, Keegan D, Richardson JS, Chlan-Fourney J, Li XM (2002) Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 321:65–68 · DOI

Cited by

Sorted by citations

Metadata

Authors
Calabrese, F., Luoni, A., Guidotti, G., Racagni, G., Fumagalli, F., & Riva, M. A.
Affiliations
University of Milan (IT)
Corresponding author
Riva, M. A.
ORCID
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2012-10-24
Volume
226
Issue
1
Pages
101-112
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
DOI
10.1007/s00213-012-2900-0
OpenAlex
W1976157209
Cited by
43
References
8
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 7 · 2013: 7
FWCI
4.80
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sunovion
  • Roche Italia
  • Dainippon Sumitomo Pharma
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
lurasidone, valproic acid, combination therapy, neuroplasticity, brain-derived neurotrophic factor, hippocampus, histone deacetylase, epigenetic regulation, atypical antipsychotics, mood stabilizers, neurotrophins
MeSH terms
Lurasidone Hydrochloride, Affect, Animals, Drug Therapy, Combination, Hippocampus, Male, Neuronal Plasticity, Thiazoles, Antipsychotic Agents, Valproic Acid, Gene Expression, Rats, Sprague-Dawley, Brain-Derived Neurotrophic Factor, Rats, Isoindoles, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review